WebAug 1, 2013 · Therefore, we undertook the present study as a follow-up to those previously reported results , in order to evaluate the incidence of uterine bleeding and the inducing factors of uterine bleeding during postoperative GnRH agonist treatment combined with estrogen-progestogen add-back therapy in Chinese women with endometriosis.
UpToDate
WebJan 1, 2015 · In order to overcome some of these side effects and enable use of GnRH agonists on a longer term basis, add-back therapies with various hormonal agents have been suggested [32,33]. ... In other parts of the world and particularly in Europe, tibolone is a popular choice for add-back therapy with long-term use of GnRH agonists [36 ... Webof conjugated estrogens as an add-back replacement drug, or HET on femoral bone mineral density (BMD) in female rats chronically treated with the long-acting GnRH agonist, buserelin acetate. Materials and methods The long-acting GnRH agonist, buserelin acetate ([D-Ser(tBu)6Pro9]GnRH; Suprecur MP 1.8; a gift from buehler equipment headquarters
ACOG Updates Guideline on Diagnosis and Treatment of Endometriosis
WebAcross both trials, 10 women — all in the elagolix groups (6 in UF-1: 3 [2.9%] in elagolix alone and 3 [1.5%] in elagolix with add-back therapy; 4 in UF-2: 1 [1%] in elagolix alone and 3 [1.6% ... WebGnRH agonists are typically used for less than 6 months without add-back therapy, or for 12 months with add-back therapy. After a woman stops taking a GnRH agonist, her … WebOct 20, 2024 · To evaluate the effectiveness of a new class of medical drugs, namely oral gonadotropin-releasing hormone (GnRH) antagonists, in the management of … crisp makers uk